When it comes to treatment for hemophilia with inhibitors, you have a therapy choice. Along with fast bleed control, you may want to consider how well your treatment fits into your lifestyle.
Here are some things to think about:
When it comes to treatment for hemophilia with inhibitors, you have a therapy choice. Along with fast bleed control, you may want to consider how well your treatment fits into your lifestyle.
Here are some things to think about:
aFEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors.
bIn patients with hemophilia A or B with inhibitors.
cIndividual doses for a joint bleed are compared and based on an 88-kg (194-lb) person.
dPatients are cautioned that the maximum injection or infusion rate must not exceed 2 units per kilogram of body weight per minute.
All information from FEIBA Package Insert.
eRedosing time does not correlate to body weight.
fMaximum daily dose.
Traveling is more convenient when everything you need to prepare and mix a dose comes in 1 compact box. And with multiple dose strengths, you’ll have fewer vials to transport. For storing supplies at home or to help make traveling even more convenient, get a Ready-to-Travel Case. It’s compact and ready to pack in your carry-on bag, backpack, or briefcase.
To order a Ready-to-Travel Case please contact a Novo Nordisk Hemophilia Community Liaison (HCL).
The MixPro® prefilled syringe means no extra steps to fill a syringe with diluent.
The MixPro® prefilled syringe means no extra steps to fill a syringe with diluent.
Once you and your health care provider decide that NovoSeven® RT is right for you, we’re here to help you successfully start your treatment.
Watch our videos to hear people with bleeding disorders talk about traveling and infusing on the go with NovoSeven® RT.
You may be eligible to try it for free.g To learn more about our trial prescription program, please call 1-844-668-6732 to speak with a NovoSecure™ Specialist.
gPatients who have been prescribed a Novo Nordisk hemophilia and rare bleeding disorder product for an FDA-approved indication, and who have commercial insurance, may be eligible to receive a limited supply of free product. Patient is not eligible if he/she participates in or seeks reimbursement or submits a claim for reimbursement to any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state health care program. Product is provided at no cost to the patient or the HCP, is not contingent on any product purchase, and the patient and HCP must not: (1) bill any third party for the free product, or (2) resell the free product.
NovoSeven® RT may cause serious side effects, including:
NovoSeven® RT (coagulation Factor VIIa, recombinant) is an injectable medicine used for:
NovoSeven® RT may cause serious side effects, including: